OSTARINE

WHAT IS MK-2866 (OSTARINE / ENOBOSARM)?

MK-2866, also known by its research names GTx-024, MK-0773, and Enobosarm, is a nonsteroidal oral SARM that binds selectively to androgen receptors. It was developed by GTx, Inc. in collaboration with Merck to help treat muscle wasting (cachexia) and osteoporosis.

The goal behind SARMs like Ostarine was to provide targeted anabolic effects—stimulating muscle and bone growth without activating androgen receptors in reproductive tissues like the prostate or sebaceous glands (where steroids commonly cause adverse effects) Dalton et al., 2013.

HOW DOES MK-2866 (OSTARINE) WORK?

MECHANISM OF ACTION

Ostarine functions by binding to androgen receptors in skeletal muscle and bone to stimulate anabolic activity, such as increased muscle protein synthesis and bone mineral density.

Unlike anabolic steroids, Ostarine does not undergo aromatization or 5-alpha-reduction, meaning it does not convert to estrogen or dihydrotestosterone (DHT)—which are responsible for many steroid-related side effects Basaria et al., 2013.

SARMs modulate androgen receptor signaling in a tissue-selective manner, influencing transcription factors and gene expression only in target tissues such as muscle, while sparing reproductive and cardiovascular systems.

LIPID METABOLISM AND HORMONAL IMPACT

Preclinical research has also shown that MK-2866 impacts lipid metabolism, decreasing leptin and adiponectin expression Dubois et al., 2017. Leptin, a hormone that regulates satiety, can influence both energy balance and fat distribution, hinting at Ostarine’s potential fat-loss properties as well.

BENEFITS OF MK-2866 (OSTARINE) FOR BODYBUILDERS AND FITNESS ENTHUSIASTS

INCREASES LEAN MUSCLE MASS

One of the most well-documented benefits of MK-2866 is its ability to increase lean body mass without the side effects associated with anabolic steroids. In a 12-week, double-blind, placebo-controlled trial, participants who received 3 mg of Ostarine daily experienced significant gains in lean muscle and improved physical performance compared to placebo (Dalton et al., Journal of Cachexia, Sarcopenia and Muscle, 2011).

PROMOTES FAT LOSS WHILE PRESERVING MUSCLE

Ostarine is highly effective during cutting cycles as it helps users retain lean muscle mass while promoting fat loss. Its tissue-selective nature means it targets muscle without significantly affecting androgen-sensitive areas like the prostate (Basaria et al., JAMA, 2013).

ENHANCES STRENGTH AND PHYSICAL PERFORMANCE

Users report noticeable improvements in strength, endurance, and recovery time, making it ideal for increasing training intensity. Ostarine’s ability to stimulate muscle protein synthesis contributes to enhanced performance in the gym (Progressive Wellness).

SUPPORTS BONE HEALTH AND DENSITY

Studies show that Ostarine may help improve bone mineral density, making it beneficial for injury prevention and long-term joint support, particularly in aging athletes or during intensive training phases (Kumar et al., Current Opinion in Supportive and Palliative Care, 2016).

ACCELERATES INJURY RECOVERY

Because MK-2866 positively impacts connective tissue and muscle regeneration, it has potential use in injury rehabilitation protocols, helping speed up recovery from strains or overuse injuries.

MK-2866 (OSTARINE) DOSAGE GUIDELINES

RECOMMENDED DOSAGE FOR MUSCLE GROWTH (BULKING)

For those using Ostarine to support muscle growth or bulking cycles, the standard dosage is:

15–25 mg per day

Cycle duration: 6 to 8 weeks

This range helps maximize lean muscle gains while minimizing the risk of side effects. Due to Ostarine’s 24-hour half-life, once-daily dosing is sufficient.

RECOMMENDED DOSAGE FOR CUTTING AND FAT LOSS

To preserve muscle while cutting body fat:

10–15 mg per day

Cycle duration: 6 to 8 weeks

This dose supports muscle retention, increased vascularity, and fat oxidation during calorie deficits without significant suppression of natural testosterone levels.

FOR INJURY RECOVERY OR MUSCLE PRESERVATION

5–10 mg per day may be sufficient for tissue healing, recovery support, or therapeutic applications like muscle preservation in aging individuals or during rehab phases (Progressive Wellness).

⚠️ Important: Post-cycle therapy (PCT) may be necessary, especially at higher dosages or extended cycles. Always consult a healthcare provider before starting MK-2866 or any SARM protocol.

CLINICALLY PROVEN BENEFITS OF MK-2866 (OSTARINE) IN MUSCLE HEALTH AND PERFORMANCE

MK-2866 (also known as Enobosarm or Ostarine) has been the subject of extensive clinical evaluation for its ability to treat muscle wasting (cachexia), sarcopenia, and other conditions involving the loss of lean body mass. Its tissue-selective action, sparing reproductive organs while targeting skeletal muscle and bone, makes it one of the most promising SARMs currently studied in human trials.

INCREASES LEAN MUSCLE MASS

In a pivotal Phase II randomized, double-blind, placebo-controlled clinical trial, 120 healthy elderly men were given 3 mg of Enobosarm daily for 12 weeks. The primary endpoint was to measure the increase in lean body mass (LBM), while the secondary endpoint evaluated improvements in physical function.

Results showed a statistically significant increase in total lean mass compared to placebo.

Participants also demonstrated improved stair-climbing ability and leg press strength.

Notably, there were no serious adverse events linked to the treatment.

This study confirmed that MK-2866 could stimulate anabolic activity in muscle tissue without the harmful side effects associated with traditional anabolic steroids (Dalton et al., Journal of Cachexia, Sarcopenia and Muscle, 2011).

PREVENTS MUSCLE WASTING (CACHEXIA) IN CANCER PATIENTS

Muscle wasting is a common complication in cancer patients, often leading to functional decline, increased morbidity, and reduced quality of life. Two major clinical trials examined the effectiveness of MK-2866 in individuals with non-small cell lung cancer and colorectal cancer experiencing cachexia.

In a Phase II, multicenter trial, cancer patients received 1 or 3 mg of Enobosarm daily for 113 days.

Results showed a significant improvement in lean body mass, as well as improvements in stair climb power and walking speed.

These outcomes were achieved without the virilizing or estrogenic effects seen with other anabolic agents (Dobs et al., Journal of Clinical Oncology, 2013).

The trials supported the notion that Enobosarm could preserve or restore muscle mass during catabolic disease states, offering a viable treatment strategy for cancer-related muscle loss.

PROMISING RESULTS IN WOMEN WITH SARCOPENIA

Sarcopenia—a condition characterized by age-related loss of muscle mass and strength—primarily affects older adults and significantly contributes to frailty, falls, and reduced independence.

A double-blind, placebo-controlled study involving 170 postmenopausal women with sarcopenia assessed the effects of MK-2866 over 12 weeks.

Women receiving Enobosarm experienced increased lean muscle mass, enhanced mobility, and better balance.

The treatment was well tolerated, and adverse events were minimal.

These findings support MK-2866’s therapeutic role in combating age-related muscle degeneration, especially in women—a demographic often underserved in clinical muscle research (Harrison et al., Current Opinion in Supportive and Palliative Care, 2019).

IMPROVES PHYSICAL FUNCTION AND REDUCES FALL RISK

In addition to increasing lean mass, MK-2866 has consistently demonstrated the ability to enhance physical performance metrics, which include:

Stair-climbing speed

Walking distance

Grip strength

Leg press endurance

These performance markers are critical in determining mobility, independence, and injury risk, particularly in older populations. Improving them with a non-steroidal, orally active compound like Enobosarm represents a major breakthrough in therapeutic muscle research.

SIDE EFFECTS OF MK-2866 (OSTARINE)

COMMON SIDE EFFECTS

While Ostarine is generally well-tolerated, users have reported dose-dependent side effects, including:

Headaches

Back pain

Libido changes

Decreased sex hormone-binding globulin (SHBG)

Basaria et al., 2013

HORMONAL IMBALANCES AND ESTROGENIC EFFECTS

Although Ostarine does not aromatize into estrogen, it can still cause testosterone suppression, which may lead to elevated estrogen levels relative to testosterone. This hormonal imbalance may result in:

Acne

Low libido

Lethargy

Gynecomastia

Mood swings / depression

High blood pressure

Testicular shrinkage

A post-cycle therapy (PCT) protocol is often recommended to help restore natural testosterone levels following use.

LIVER TOXICITY RISK

Despite SARMs being marketed as safer alternatives, ergogenic dosages of Ostarine can still result in elevated liver enzymes, indicating potential hepatic stress. Though the risk appears low at clinical doses, liver function should be monitored during use FDA Warning, 2017.

OSTARINE DOSAGE AND CYCLING: HOW TO USE MK-2866 EFFECTIVELY

→ RECOMMENDED DOSAGE FOR OSTARINE (MK-2866)

Ostarine, also known as MK-2866, is one of the most studied and beginner-friendly SARMs (Selective Androgen Receptor Modulators). Dosage depends on your training goal—whether it’s cutting, bulking, or body recomposition.

→ Men – Performance Use

10–20 mg per day for 6–8 weeks

→ 10 mg/day supports muscle preservation during a cut

→ 20 mg/day enhances lean mass and strength during a recomp or bulk

→ Women – Performance Use

5–10 mg per day for 4–6 weeks

Ostarine is often considered one of the more female-tolerable SARMs, but women should still use conservative dosing and limit cycle duration to avoid androgenic side effects.

→ Therapeutic Range

In clinical trials for muscle wasting and osteoporosis, Ostarine was administered at 1–3 mg/day and still showed statistically significant improvements in lean body mass and physical performance

“Even low doses of Ostarine (~3 mg/day) increased muscle mass and strength in elderly subjects with minimal side effects.”

— Dalton et al., Journal of Gerontology

For more background on its mechanism and safety profile, read Is Ostarine Safe? and Ostarine MK-2866 Benefits And Side Effects.

→ OPTIMAL CYCLE LENGTH AND STRUCTURE

Ostarine cycles are typically 6–8 weeks for men and 4–6 weeks for women. Prolonged use or higher doses increase the risk of HPTA suppression, despite MK-2866 being non-steroidal.

→ Beginner Male Cycle

→ Weeks 1–8: 10–15 mg/day

→ Follow with 4 weeks of post-cycle therapy (see below)

→ Cutting or Recomp Cycle Example

→ Weeks 1–8: 20 mg/day Ostarine

→ Stack with Cardarine (GW-501516) for enhanced endurance and fat loss

→ DOSING FREQUENCY AND TIMING

Ostarine has a 24-hour half-life, allowing for once-daily oral dosing. Take it at the same time every day—morning or pre-workout—to maintain stable serum concentrations and maximize muscle protein synthesis.

→ POST-CYCLE THERAPY (PCT) FOR OSTARINE

Though Ostarine is considered a mild SARM, it still suppresses natural testosterone—especially at higher doses or longer durations. A PCT protocol is strongly recommended for men.

→ Men’s PCT Protocol

→ Duration: 4 weeks post-cycle

→ Supplements:

→ DHEA – 100 mg/day

→ ZMT – 6 capsules nightly for testosterone and sleep support

→ Tamoxifen or Clomid for aggressive hormonal recovery, if dosed at 20 mg or more for 8 weeks

→ Women’s PCT Consideration

Women usually do not require PCT at low doses. However, if signs of androgenic effects emerge or cycles exceed 6 weeks, post-cycle support may be considered on a case-by-case basis.

→ TIME OFF BETWEEN OSTARINE CYCLES

Use the “time on = time off” rule to allow full hormonal recovery:

→ 8-week cycle = 8-week break (including PCT)

This approach reduces long-term suppression risk and helps preserve muscle and strength gains over multiple cycles.

KEEP OUT OF REACH OF CHILDREN

Should BE AT ROOM TEMPERATURE 15-30•c (59-86•F)

PROTECT FROM SUNLIGHT

MANUFACTURED AND DISTRIBUTED BY:

MAGMA pharmaceuticals.Ltd

ANDARINE

WHAT IS S-4 (ANDARINE) | GTX-007 EXPLAINED

INTRODUCTION TO S-4 (ANDARINE)

S-4, also known as Andarine or GTX-007, is an orally bioavailable, non-steroidal selective androgen receptor modulator (SARM). Originally developed by GTX Inc., Andarine is a partial agonist of the androgen receptor (AR), designed to selectively stimulate anabolic activity in muscle and bone tissues without the undesirable side effects of traditional anabolic steroids.

SARMs like S-4 were developed in the early 2000s as alternatives to steroidal androgen receptor agonists such as testosterone and dihydrotestosterone (DHT), which are associated with liver toxicity, cardiovascular risks, and prostate enlargement Dalton et al., Current Opinion in Clinical Nutrition & Metabolic Care, 2007.

WHY WAS S-4 ABANDONED IN CLINICAL TRIALS?

Although S-4 showed promising anabolic activity in preclinical studies, it never advanced to Phase I human trials due to visual side effects. These effects were linked to the binding of S-4 to ocular androgen receptors, resulting in temporary vision disturbances such as night blindness and a yellow tint. The severity and frequency of these effects led researchers to discontinue clinical development of S-4 despite its efficacy in muscle and bone tissue Kearbey et al., Endocrinology, 2007.

HOW DOES S-4 (ANDARINE) WORK?

MECHANISM OF ACTION

S-4 works primarily by binding selectively to androgen receptors in skeletal muscle and bone, mimicking the effects of testosterone but with reduced activity in androgen-sensitive tissues like the prostate. Unlike DHT, which is a full androgen receptor agonist across all tissues, S-4 acts as a full agonist in muscle but only a partial agonist in the prostate Kearbey et al., Endocrinology, 2007.

Additionally, S-4 may inhibit DHT binding, which can reduce side effects related to excess androgenic activity.

HORMONAL SUPPRESSION

Although S-4 does not aromatize into estrogen, it suppresses natural testosterone production by reducing levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). As a result, post-cycle therapy (PCT) is recommended after S-4 use to help restore hormonal balance.

BENEFITS OF S-4 (ANDARINE)

INCREASES LEAN MUSCLE MASS

S-4 has demonstrated significant anabolic activity in skeletal muscle. One of the earliest pivotal studies was conducted in orchidectomized (castrated) male rats, where S-4 restored muscle mass and strength to levels seen in intact animals.

Dosage: 3 or 10 mg/kg of S-4 for 8 weeks

Results: Restoration of soleus muscle mass, levator ani muscle, and improved strength

Comparison: Similar anabolic effect to DHT, but with much less stimulation of androgenic organs like the prostate and seminal vesicles

While DHT increased prostate size by nearly 200%, S-4 caused only 16–17% growth, indicating a much more tissue-selective anabolic profile Kearbey et al., Endocrinology, 2007.

ENHANCES BONE MINERAL DENSITY

In the same animal studies, S-4 significantly improved total body bone mineral density (BMD), offering protective effects against age-related bone loss.

S-4’s Role: Direct activation of androgen receptors in bone tissue

Key Difference: Unlike testosterone, S-4 does not aromatize into estrogen, and its bone effects are independent of estrogen receptor activity

Comparison: S-4 outperformed DHT in bone mineral density improvements without affecting estrogen levels

These findings suggest S-4 could be a promising candidate for osteoporosis prevention, especially in populations where estrogen therapy is contraindicated Kearbey et al., Endocrinology, 2007.

LIMITATIONS AND FINAL CONSIDERATIONS

WHY S-4 ISN’T USED IN HORMONE REPLACEMENT THERAPY

Despite its muscle-building properties, S-4 is not viable for hormone replacement therapy (HRT) because it:

Does not convert to estrogen, which plays a vital role in male and female health

Causes testosterone suppression, requiring post-cycle intervention

Has vision-related side effects that raise long-term safety concerns

CURRENT STATUS AND RESEARCH DIRECTION

While S-4 is not FDA-approved, it remains popular in research and underground bodybuilding communities. More clinical research is required to:

Develop derivatives of S-4 that avoid visual side effects

Confirm long-term safety in human populations

Evaluate its therapeutic potential in sarcopenia, osteoporosis, and muscle-wasting diseases

⚠️ Disclaimer: S-4 (Andarine) is currently classified as a research chemical and is not approved for human use outside of clinical studies.

S-4 (ANDARINE) SIDE EFFECTS, LEGALITY, AND SAFETY PROFILE

KNOWN AND REPORTED SIDE EFFECTS OF S-4 (ANDARINE)

Like other commonly used selective androgen receptor modulators (SARMs), S-4 (Andarine) is associated with several potential side effects. Due to the lack of long-term human efficacy and toxicity studies, the full extent of health risks remains largely unknown.

Although preclinical animal trials did not report many adverse effects, as S-4 was never tested in human clinical trials, one of the most prominent and unique side effects reported from user experiences is vision impairment.

VISION IMPAIRMENT: A UNIQUE RISK OF ANDARINE

S-4 demonstrates high binding affinity for androgen receptors located in the eye—specifically in the cornea, lens, iris, and ciliary body. These ocular structures contain androgen receptors, and SARMs like S-4 can bind to these receptors, causing disruption in visual function Dubois et al., The Ocular Surface, 2020.

At higher doses, users commonly report:

Blurred or yellow-tinted vision

Night blindness

Visual flashes or flickering

These effects are typically temporary and dose-dependent, but due to their prevalence, they were a major reason S-4 was discontinued from clinical development.

HORMONAL SUPPRESSION AND METABOLIC EFFECTS

Like all SARMs, S-4 suppresses natural testosterone production—even though it is considered among the least suppressive of the mainstream SARMs.

COMMON HORMONAL AND ANDROGENIC SIDE EFFECTS INCLUDE:

Acne

Low libido

Lethargy

Gynecomastia (male breast tissue growth)

Depressed mood

Elevated blood pressure

Shrinkage in testicular size

In addition, S-4 does not aromatize into estrogen, yet it can still indirectly cause imbalances in estrogen levels. The imbalance between suppressed testosterone and fluctuating estrogen may further increase the risk of the above symptoms.

Studies also report reductions in sex hormone-binding globulin (SHBG) and high-density lipoprotein (HDL), the so-called “good cholesterol”, which raises concerns about cardiovascular health Narayanan et al., JAMA, 2018.

ADDITIONAL COMMONLY REPORTED SIDE EFFECTS OF SARMS IN GENERAL:

Headaches

Dry mouth

Constipation

Nausea

Dyspepsia (indigestion)

Upper respiratory tract infections (URIs)

LIVER TOXICITY CONCERNS

Though SARMs are marketed as having a lower liver toxicity risk compared to anabolic steroids, there is still potential for hepatic stress. Some users may experience elevated liver enzyme levels—a common marker for liver strain or injury.

⚠️ At higher “ergogenic” or bodybuilding doses, SARMs like S-4 may still carry hepatotoxic risks, even though therapeutic doses may present a lower risk profile FDA SARMs Advisory, 2017.

PHARMACOKINETICS AND HALF-LIFE OF S-4

ABSORPTION AND BIOAVAILABILITY

The average terminal half-life of S-4 in animals is about 4 hours. After oral dosing, it is:

Rapidly absorbed

Highly bioavailable

Peak plasma levels occur within 48–84 minutes Kearbey et al., Endocrinology, 2007

This relatively short half-life requires more frequent dosing to maintain stable blood concentrations and heightens the need for proper post-cycle therapy (PCT).

IMPORTANCE OF POST-CYCLE THERAPY (PCT)

Due to testosterone suppression and potential hormonal imbalances, PCT should begin immediately after concluding S-4 use to help restore normal endocrine function and prevent long-term side effects such as low testosterone syndrome.